Yuxi Zhu

发表

Corrigendum: Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate toward tumour blood vessels

Ruth J. Muschel, Masahiro Hiraoka, Hiroshi Harada, 2013, Nature Communications.

HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs

M. Yoshimura, M. Hiraoka, S. Itasaka, 2014, Scientific Reports.

Efficacy and safety of anti-angiogenesis medicines for advanced soft tissue sarcoma: a meta-analysis

Yuxuan Wang, Yuxi Zhu, X. Dai, 2020, Translational cancer research.

Combination of the EP and Anti-PD-1 Pathway or Anti-CTLA-4 for the Phase III Trial of Small-Cell Lung Cancer: A Meta-Analysis

Yuxi Zhu, jinmin xue, Abdulhakim A. A. Abunasser, 2021, Journal of oncology.

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study

W. Feng, H. Pan, Xiaorong Dong, 2021, EClinicalMedicine.

Estimation of Hub Genes and Infiltrating Immune Cells in Non-Smoking Females with Lung Adenocarcinoma by Integrated Bioinformatic Analysis

Yuxi Zhu, Xin Li, Jie Li, 2020, Medical science monitor : international medical journal of experimental and clinical research.

Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors.

M. Hiraoka, Xuejun Xie, S. Itasaka, 2008, Biochemical and biophysical research communications.

Down‐regulation of RCC1 sensitizes immunotherapy by up‐regulating PD‐L1 via p27kip1/CDK4 axis in non‐small cell lung cancer

Yuxi Zhu, Maoxi Zhong, X. Zeng, 2021, Journal of cellular and molecular medicine.

A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and metastatic activity of tumor cells.

H. Iwata, Y. Teramura, M. Hiraoka, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study.

Yuxi Zhu, S. Qin, Zhong Zuo, 2021, American journal of cancer research.

A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4-inhibitor drugs; a multistate transition model

Lang Li, J. Caterino, M. Donneyong, 2021, medRxiv.

Yuxi Zhu, Yang Song, J. Xue, 2022, Cells.

Regulation of the angiotensin II-p22phox-reactive oxygen species signaling pathway, apoptosis and 8-oxoguanine-DNA glycosylase 1 retrieval in hyperoxia-induced lung injury and fibrosis in rats

Y. Zhu, Zhong-yi Lu, Yuxi Zhu, 2017, Experimental and therapeutic medicine.

Effect of low dose of berberine on the radioresistance of cervical cancer cells via a PI3K/HIF-1 pathway under nutrient-deprived conditions

Yuxi Zhu, Yu Wang, X. Zeng, 2020, International journal of radiation biology.

Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study

Yuxi Zhu, S. Qin, Zhong Zuo, 2023, Frontiers in Cardiovascular Medicine.

Microenvironments and Cellular Characteristics in the Micro Tumor Cords of Malignant Solid Tumors

M. Hiraoka, H. Harada, Yuxi Zhu, 2012, International journal of molecular sciences.

A Giant Lung Tumor Disappeared After Crizotinib Treatment in an Elder Heavy Smoker: a Case Report

H. Tie, Yuxi Zhu, Zhong Zuo, 2021, SN Comprehensive Clinical Medicine.

UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α

M. Sonobe, H. Date, M. Yoshimura, 2015, Nature Communications.

Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer

Yuxi Zhu, Jie Li, Wenwen Xu, 2020, Oncology letters.

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

M. Yoshimura, M. Hiraoka, R. Muschel, 2012, Nature Communications.

A Comprehensive Multiomics Analysis Identified Ubiquilin 4 as a Promising Prognostic Biomarker of Immune-Related Therapy in Pan-Cancer

Yuxi Zhu, Jie Li, Yi Liu, 2021, Journal of oncology.

Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations

Xianquan Zhang, Yuxi Zhu, Shumei Wang, 2019, Medical science monitor : international medical journal of experimental and clinical research.

Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis

Yuxi Zhu, Zhi Wang, J. Xue, 2020, Translational cancer research.

LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis

M. Yoshimura, M. Hiraoka, E. Hammond, 2016, Oncotarget.

Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer Analysis

Yuxi Zhu, Jie Li, Maoxi Zhong, 2021, Frontiers in Molecular Biosciences.

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC

Yuxi Zhu, Jie Li, Maoxi Zhong, 2022, Journal of inflammation research.

Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy

M. Hiraoka, H. Harada, L. Zeng, 2011, Cancers.

A multistate transition model for statin‐induced myopathy and statin discontinuation

D. Zeng, Lang Li, M. Donneyong, 2021, CPT: pharmacometrics & systems pharmacology.

Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments

Mengxia Li, Yuxi Zhu, Xiaoyan Dai, 2023, Cancers.

PD-1/PD-L1 Inhibitors vs. Chemotherapy For Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials

Yuxi Zhu, Maoxi Zhong, X. Zeng, 2021 .

Aberrant IDH3α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis

X Wang, M Hiraoka, M. Yoshimura, 2014, Oncogene.